awmsg logo



romiplostim (Nplate®)


Reference No. 3103

Publication date:
06/03/2019


Appraisal information

romiplostim (Nplate®) 125 micrograms powder for solution for injection


Company: Amgen Ltd
BNF category: Nutrition and blood
NMG meeting date: 09/01/2019
AWMSG meeting date: 13/02/2019
   
   
Submission Type: Limited Submission
Status: Recommended
Advice No: 0119
Ratification by Welsh Government: 05/03/2019

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ratification by
Welsh Government

AWMSG advice

Romiplostim (Nplate®) is recommended as an option for use within NHS Wales for the treatment of chronic immune (idiopathic) thrombocytopenic purpura (ITP) patients aged 1 year to < 18 years who are refractory to other treatments (for example, corticosteroids, immunoglobulins). This recommendation applies only in circumstances where the approved Patient Access Scheme (PAS) is utilised or where the list/contract price is equivalent or lower than the PAS price.
AWMSG Secretariat Appraisal Report (ASAR)
Download
Final Appraisal Recommendation (FAR)
Download